Quantitative risk analysis for N-methyl pyrrolidone using physiologically based pharmacokinetic and benchmark dose modeling

Toxicological Sciences

Volumn 113, Issue 2, 2009, Pages 468-482

  Poet, Torka S ^a   Kirman, Chris R ^b   Bader, Michael ^c   Van thriel, Christoph ^d   Gargas, Michael L ^e   Hinderliter, Paul M ^a  

^a Biological Monitoring and Modeling   (United States)

^b Sapphire Group Inc   (United States)

^c HANNOVER MEDICAL SCHOOL   (Germany)

^d LEIBNIZ RESEARCH CENTRE FOR WORKING ENVIRONMENT AND HUMAN FACTORS   (Germany)

^e Sapphire Group Inc   (United States)

Author keywords

Benchmark dose; Exposure assessment; Human equivalent concentration; PBPK; Risk assessment

Indexed keywords

1 METHYL 2 PYRROLIDINONE;

ADULT; ARTICLE; BIOLOGICAL MONITORING; BIRTH WEIGHT; BLOOD LEVEL; CONCENTRATION RESPONSE; CONTROLLED STUDY; FETUS WEIGHT; GESTATION PERIOD; HUMAN; HUMAN EXPERIMENT; MALE; MATERNAL BLOOD; MICHAELIS MENTEN KINETICS; NONBIOLOGICAL MODEL; NORMAL HUMAN; OCCUPATIONAL EXPOSURE; OCCUPATIONAL SAFETY; PRENATAL EXPOSURE; QUANTITATIVE ANALYSIS; RISK ASSESSMENT; TOXICOKINETICS;

ADULT; ANIMALS; BENCHMARKING; DOSE-RESPONSE RELATIONSHIP, DRUG; ENVIRONMENTAL EXPOSURE; FEMALE; HUMANS; MALE; MICE; MODELS, ANIMAL; MODELS, CHEMICAL; PREGNANCY; PYRROLIDINONES; RATS; RISK ASSESSMENT; STRESS, PHYSIOLOGICAL; YOUNG ADULT;

RATTUS; RODENTIA;

EID: 75249102549     PISSN: 10966080     EISSN: 10960929     Source Type: Journal    
DOI: 10.1093/toxsci/kfp264     Document Type: Article

References (51)

1. Akesson, B., Carnerup, M.A., and Jonsson, B.A. (2004). Evaluation of exposure biomarkers from percutaneous absorption of N-methyl-2-pyrrolidone. Scand. J. Work Environ. Health 30, 306-312.
2. Akesson, B., and Jonsson, B.A. (1997). Major metabolic pathway for N-methyl-2-pyrrolidone in humans. Drug Metab. Dispos. 25, 267-269.
3. Akesson, B., and Jonsson, B.A. (2000). Biological monitoring of N-methyl-2-pyrrolidone using 5-hydroxy-N-methyl-2-pyrrolidone in plasma and urine as the biomarker. Scand. J. Work Environ. Health 26, 213-218.
4. Akesson, B., and Paulsson, K. (1997). Experimental exposure of male volunteers to N-methyl-2-pyrrolidone (NMP): Acute effects and pharmacokinetics of NMP in plasma and urine. Occup. Environ. Med. 54, 236-240.
5. American Industrial Hygiene Association. (1997). Workplace Environmental Exposure Level Guide: N-Methyl-2-Pyrrolidone. Cincinnati, OH.
6. Bader, M., Keener, S.A., and Wrbitzky, R. (2005). Dermal absorption and urinary elimination of N-methyl-2-pyrrolidone. Int. Arch. Occup. Environ. Health 78, 673-676.
7. Bader, M., and van Thriel, C. (2006). Human volunteer study on biomarkers of N-methyl-2-pyrrolidone (NMP) after inhalation exposure. Report for the NMP Producers Group, Washington, DC.
8. Bader, M., Wrbitzky, R., Blaszkewicz, M., Schaper, M., and van Thriel, C. (2008). Human volunteer study on the inhalational and dermal absorption of N-methyl-2-pyrrolidone (NMP) from the vapour phase. Arch. Toxicol. 82, 13-20.
9. Bader, M., Wrbitzky, R., Blaszkewicz, M., and van Thriel, C. (2007). Human experimental exposure study on the uptake and urinary elimination of N-methyl-2-pyrrolidone (NMP) during simulated workplace conditions. Arch. Toxicol. 81, 335-346.
10. Becci, P.J., Knickerbocker, M.J., Reagan, E.L., Parent, R.A., and Burnette, L.W. (1982). Teratogenicity study of N-methylpyrrolidone after dermal application to Sprague-Dawley rats. Fundam. Appl. Toxicol. 2, 73-76.
11. Brown, R.P., Delp, M.D., Lindstedt, S.L., Rhomberg, L.R., and Beliles, R.P. (1997). Physiologically parameter values for physiologically based pharma-cokinetic models. Toxicol. Ind. Health 13, 407-484.
12. Clewell, H.J., and Andersen, M.E. (1996). Use of physiologically based pharmacokinetic modeling to investigate individual versus population risk. Toxicology 111, 315-329.
13. Clewell, H.J., Teeguarden, J., McDonald, T., Sarangapani, R., Lawrence, G., Covington, T., Gentry, R., and Shipp, A. (2002). Review and evaluation of the potential impact of age- and gender-specific pharmacokinetic differences on tissue dosimetry. Crit. Rev. Toxicol. 32, 329-389.
14. Corley, R.A., Markham, D.A., Banks, C., Delorme, P., Masterman, A., and Houle, J.M. (1997). Physiologically based pharmacokinetics and the dermal absorption of 2-butoxyethanol vapor by humans. Fundam. Appl. Toxicol. 39, 120-130.
15. Corley, R.A., Mast, T.J., Carney, E.W., Rogers, J.M., and Daston, G.P. (2003). Evaluation of physiologically based models of pregnancy and lactation for their application in children's health risk assessments. Crit. Rev. Toxicol. 33, 137-21.
16. Deutsche Forschungsgemeinschaft (DFG). (2006). Greim, H., Ed. 2006. Occupational Toxicants, Critical Data Evaluation for MAK Values and Classification of Carcinogens (including 41st supplement), N-Methyl-2-Pyrrolidone (vapour). Wiley-VCH, Weinheim, Germany.
17. Flick, B., Talsness, C.E., Jackh, R., Buesen, R., and Klug, S. (2009). Embryotoxic potential of N-methyl-pyrrolidone (NMP) and three of its metabolites using the rat whole embryo culture system. Toxicol. Appl. Pharmacol. 237, 154-167.
18. Gentry, P.R., Covington, T.R., Andersen, M.E., and Clewell, H.J., III. (2002). Application of a physiologically based pharmacokinetic model for isopropanol in the derivation of a reference dose and reference concentration. Regul. Toxicol. Pharmacol. 36, 51-68.
19. Gentry, P.R., Covington, T.R., and Clewell, H.J. (2003). Evaluation of the potential impact of pharmacokinetic differences on tissue dosimetry in offspring during pregnancy and lactation. Regul. Toxicol. Pharmacol. 38, 1-16.
20. Ghantous, H. (1995). In Oral, Dermal, and Inhalation Pharmacokinetics and Disposition of [2-14 C] NMP in the Rat. Report for E.I. du Pont de Nemours and Company, Haskell Laboratory for Toxicology and Industrial Medicine, Wilmington, DE.
21. Hellwig, J.G., and Hildebrand, B.C. (1999). In N-Methylpyrrolidone (NMP)-Two-Generation Reproduction Toxicity Study in Wistar Rats Administration in the Diet. Department of Toxicology of BASF Aktienge-sellschaft, Ludwigshafen, Germany.
22. Hytten, F.E., and Eg, R. (1971). Maternal water metabolism in pregnancy. Proc R Soc Med 64, 1072.
23. ICRP. (1975). Report of the Task Group on Reference Man: ICRP Publication 23. Elsevier Science Inc., Tarrytown, NY.
24. IRIS. (2009). Integrated Risk Information System Database Download Available at: http://www.epa.gov/iris.
25. Jepson, G.W., Hoover, D.K., Black, R.K., McCafferty, J.D., Mahle, D.A., and Gearhart, J.M. (1994). A partition coefficient determination method for nonvolatile chemicals in biological tissues. Fundam. Appl. Toxicol. 22, 519-524.
26. Jonsson, B., and Akesson, B. (1997). Determination of 5-hydroxy-N-methylpyrrolidone and 2-hydroxy-N-methylsuccinimide in human urine. J Chromatogr B 694, 151-158.
27. Jonsson, F., Bois, F., and Johanson, G. (2001). Physiologically based pharmacokinetic modeling of inhalation exposure of humans to dichloromethane during moderate to heavy exercise. Toxicol. Sci. 59, 209-218.
28. Lee, K.P., Chromey, N., Culik, R., Barnes, J., and Schneider, P. (1987). Toxicity of N-methylpyrrolidone (NMP): Teratogenic, subchronic, and two-year inhalation studies. Fundam. Appl. Toxicol. 9, 222-235.
29. Ligocka, D., Lison, D., and Haufroid, V. (2003). Contribution of CYP2E1 to N-methyl-2-pyrrolidone metabolism. Arch. Toxicol. 77, 261-266.
30. Midgley, I., Hood, A.J., Chasseaud, L.F., Brindley, C.J., Baughman, S., and Allan, G. (1992). Percutaneous-absorption of co-administered N-methyl-2-[C-14]pyrrolidinone and 2-[C-14]pyrrolidinone in the rat. Food Chem. Toxicol. 30, 57-64.
31. O'Flaherty, E.J. (1994). Physiologically based pharmacokinetic models in developmental toxicology. Risk Analysis 14, 605-611.
32. O'Flaherty, E.J., Scott, W., Schreiner, C., and Beliles, R.P. (1992). A physiologically based kinetic model of rat and mouse gestation: Disposition of a weak acid. Toxicol. Appl. Pharmacol. 112, 245-256.
33. Organisation for Economic Co-operation and Development (OECD). (2007). SIDS Initial Assessment Report for SIAM 24: 1-Methyl-2-Pyrrolidone Available at: http://www.oecd.org/LongAbstract/0,3425,en_2649_34379_43514942_1_1_1_1,00.html.
34. Payan, J.P., Beydon, D., Fabry, J.P., Boudry, I., Cossec, B., and Ferrari, E. (2002). Toxicokinetics and metabolism of N-[14C]methylpyrrolidone in male Sprague-Dawley rats. A saturable NMP elimination process. Drug Metab. Dispos. 30, 1418-1424.
35. Payan, J.P., Boudry, I., Beydon, D., Fabry, J.P., Grandclaude, M.C., Ferrari, E., and Andre, J.C. (2003). Toxicokinetics and metabolism of N-[(14)C]N-methyl-2-pyrrolidone in male sprague-dawley rats: In vivo and in vitro percutaneous absorption. Drug. Metab. Dispos. 31, 659-669.
36. Saillenfait, A.M., Gallissot, F., Langonne, I., and Sabate, J.P. (2002). Developmental toxicity of N-methyl-2-pyrrolidone administered orally to rats. Food Chem. Toxicol. 40, 1705-1712.
37. Saillenfait, A.M., Gallissot, F., and Morel, G. (2003). Developmental toxicity of N-methyl-2-pyrrolidone in rats following inhalation exposure. Food Chem. Toxicol. 41, 583-588.
38. Saillenfait, A.M., Sabate, J.P., and Gallissot, F. (2007a). Comparative developmental toxicities of the three major metabolites of N-methyl-2-pyrrolidone after oral administration in rats. J. Appl. Toxicol. 27, 571-581.
39. Saillenfait, A.M., Gallissot, F., and Sabate, J.P. (2007b). Developmental toxic effects of N-ethyl-2-pyrrolidone administered orally to rats. J. Appl. Toxicol. 27, 491-497.
40. Scientific Committee on Occupational Exposure Limits (SCOEL). (2007). Recommendation from the scientific committee on occupational exposure limits for N-methyl-2-pyrrolidone. Scientific Committee on Occupational Exposure Limits, National Toxicology Program, Brussels, Belgium.
41. Solomon, H.M., Burgess, B.A., Kennedy, G.L., Jr., and Staples, R.E. (1995). 1-Methyl-2-pyrrolidone (NMP): Reproductive and developmental toxicity study by inhalation in the rat. Drug Chem. Toxicol. 18, 271-293.
42. Staples, R.E. (1990). 1-Methyl-2-pyrrolidinone (NMP): Reproductive and developmental toxicity in the rat. Haskell Laboratory for Toxicology and Industrial Medicine, Newark, DE.
43. Sweeney, L.M., Tyler, T.R., Kirman, C.R., Corley, R.A., Reitz, R.H., Paustenbach, D.J., Holson, J.F., Whorton, M.D., Thompson, K.M., and Gargas, M.L. (2001). Proposed occupational exposure limits for select ethylene glycol ethers using PBPK models and Monte Carlo simulations. Toxicol. Sci. 62, 124-139.
44. Thoresen, M., and Wesche, J. (1988). Doppler measurements of changes in human mammary and uterine blood-flow during pregnancy and lactation. Acta Obstet. Gynecol. Scand. 67, 741-745.
45. Thornton, S.R. (1999). Two-Generation Reproduction Toxicity Study with N-Methylpyrrolidone (Nm) in Sprague-Dawley Rats Administration in the Diet. Huntingdon Life Sciences, Washington, DC.
46. Tietz, N.W. (Ed.). (1995). Clinical Guide to Laboratory Tests, 3rd ed. W.B. Saunders Company, Lexington, KY.
47. U.S. Environmental Protection Agency (USEPA). (2000). Benchmark Dose Technical Guidance Document. Risk Assessment Forum, U.S. Environmental Protection Agency, Washington, DC.
48. van Thriel, C., Blaszkewicz, M., Schaper, M., Juran, S.A., Kleinbeck, S., Kiesswetter, E., Wrbitzky, R., Stache, J., Golka, K., and Bader, M. (2007). Chemosensory effects during acute exposure to N-methyl-2-pyrrolidone (NMP). Toxicol. Lett. 175, 44-56.
49. Wells, D.A., and Digenis, G.A. (1988). Disposition and metabolism of double-labeled [3h and 14c] N-methyl-2-pyrrolidinone in the rat. Drug Metab. Dispos. 16, 243-249.
50. Wells, D.A., Hawi, A.A., and Digenis, G.A. (1992). Isolation and identification of the major urinary metabolite of N-methylpyrrolidinone in the rat. Drug Metab. Dispos. 20, 124-126.
51. Xiaofei, E., Wada, Y., Nozaki, J., Miyauchi, H., Tanaka, S., Seki, Y., and Koizumi, A. (2000). A linear pharmacokinetic model predicts usefulness of N-methyl-2-pyrrolidone (NMP) in plasma or urine as a biomarker for biological monitoring for NMP exposure. J. Occup. Health 42, 321-327.